GSMS Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 60429-641-30), (b) 90-count bottle...
FDA Drug Recall #D-0271-2019 — Class II — October 29, 2018
Recall Summary
| Recall Number | D-0271-2019 |
| Classification | Class II — Moderate risk |
| Date Initiated | October 29, 2018 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Sciegen Pharmaceuticals Inc |
| Location | Hauppauge, NY |
| Product Type | Drugs |
| Quantity | 18,760 HDPE bottles |
Product Description
GSMS Irbesartan Tablets, USP, 150 mg, (a) 30-count bottle (NDC 60429-641-30), (b) 90-count bottle (NDC 60429-641-90), Rx Only, Manufactured by ScieGen Pharmaceuticals, Inc. Hauppauge, NY 11788, Marketed by: GSMS Incorporated Camarillo, CA 93012 USA.
Reason for Recall
CGMP Deviations: FDA laboratory testing confirmed presence of an impurity, N-nitrosodimethylamine (NDEA) in product.
Distribution Pattern
Nationwide
Lot / Code Information
60429-641-90 Irbesartan 150mg Tablets, 90 Count Bottle B161003 Sep-19 B161004 Sep-19 B161006 Sep-19 B161007 Sep-19 B161008 Nov-19 B161009 Nov-19 B161010 Nov-19 C161001 Feb-20 C161003 May-20 60429-641-30 Irbesartan 150mg Tablets, 30 Count Bottle GS019526 Nov-19 GS020252 Nov-19 GS020958 Nov-19
Other Recalls from Sciegen Pharmaceuticals Inc
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0354-2023 | Class III | Gabapentin Tablets, USP 600 mg, 500 tablets per... | Feb 17, 2023 |
| D-0267-2019 | Class II | Westminister Irbesartan Tablets, USP, 75 mg (a)... | Oct 29, 2018 |
| D-0268-2019 | Class II | Westminister Irbesartan Tablets, USP, 150 mg, (... | Oct 29, 2018 |
| D-0270-2019 | Class II | GSMS Irbesartan Tablets, USP, 75 mg, 30-count b... | Oct 29, 2018 |
| D-0272-2019 | Class II | GSMS Irbesartan Tablets, USP, 300 mg,(a) 30-cou... | Oct 29, 2018 |
Frequently Asked Questions
cGMP stands for Current Good Manufacturing Practice — the FDA's regulations governing drug manufacturing quality. A cGMP recall means the company failed to follow required manufacturing standards. This could involve inadequate testing, poor environmental controls, documentation failures, or process deviations. cGMP recalls do not always mean the product is directly harmful — in many cases, quality records are insufficient to confirm the product meets specifications. However, the FDA requires a recall because without proper documentation, product quality cannot be assured. These are often Class II or Class III recalls.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.